Guardant Health, Inc. ( GH ) is a cancer genomics diagnostics company. GH leverages the SMART platform, which spans screening, therapy selection, minimal residual disease (MRD), and surveillance across all stages of cancer. GH’s business segments include Oncology as the anchor, Screening, and Biopharma & Data. InMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science f ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Guardant Health Inc. (NASDAQ:GH) is one of the best-performing stocks on Thursday. Guardant Health soared to a fresh record high on Thursday, as investors took heart from an impressive earnings performance and a higher growth outlook for the full-year period. During the trading session, Guardant Health Inc. (NASDAQ:GH) jumped to its highest level of $95.88 before paring gains to end the day just up by 27.87 percent at $92.41 apiec ...

Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry. Narweena’s research process is focused on company and industry fundamentals with the goal of uncovering unique insights. Narweena has a high risk appetite and a long-term ...

Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry. Narweena’s research process is focused on company and industry fundamentals with the goal of uncovering unique insights. Narweena has a high risk appetite and a long-term ...

TRENDING: You Don't Have To Dig Far To Cash In On Rare EarthsGuardant Health (GH) stock rocketed Thursday on an impressive beat-and-raise earnings report that included 40% volume growth from its oncology division.That 40% volume growth for oncology tests was a "wow," William Blair analyst Andrew Brackmann said in a report. The company's suite of liquid biopsy tests, including Guardant360, use genomic profiling to determine the drivers of a patient's cancer. This helps doctors select the right, targeted trea ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Shares of Guardant Health Inc. (GH) are up over 25% at $90 in premarket trading on Thursday, after the company reported exceptionally strong financial results for the quarter ended September 30, 2025, and raised its full-year 2025 outlook.This commercial-stage precision oncology company Guardant360 Liquid test and Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the FDA to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection w ...

Core Viewpoint - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article highlights that users may face access issues if they have an ad-blocker enabled [1] - It suggests disabling ad-blockers and refreshing the page to proceed [1]

Core Insights - Guardant Health reported a revenue of $265.2 million for the quarter ended September 2025, reflecting a year-over-year increase of 38.5% [1] - The earnings per share (EPS) was -$0.39, an improvement from -$0.45 in the same quarter last year, with an EPS surprise of +18.75% compared to the consensus estimate of -$0.48 [1] - The revenue exceeded the Zacks Consensus Estimate of $234.58 million by 13.05% [1] Financial Performance Metrics - Total oncology tests performed reached 74,000, surpassing the average estimate of 66,824 by three analysts [4] - Revenue from oncology was $184.4 million, exceeding the average estimate of $164.62 million from four analysts [4] - Revenue from biopharma and data was $54.73 million, compared to the average estimate of $48.38 million [4] - Revenue from screening was $24.11 million, significantly higher than the estimated $16.31 million [4] - Revenue from licensing and other sources was $1.95 million, slightly below the average estimate of $2.35 million [4] Stock Performance - Guardant Health's shares have returned +11.4% over the past month, outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Guardant Health reported a quarterly loss of $0.39 per share, better than the Zacks Consensus Estimate of a loss of $0.48, and improved from a loss of $0.45 per share a year ago, resulting in an earnings surprise of +18.75% [1] - The company achieved revenues of $265.2 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 13.05% and showing a significant increase from $191.48 million in the same quarter last year [2] - Guardant Health's stock has increased by approximately 127.8% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] Financial Performance - Over the last four quarters, Guardant Health has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $251.41 million, and for the current fiscal year, it is -$1.84 on revenues of $921.37 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Guardant Health belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]